Edgar Filing: AGENUS INC - Form 4

AGENUS I Form 4 July 01, 201 FORN Check th if no lon subject to Section Form 4 Form 5 obligation may con <i>See</i> Insta 1(b).	6 A 4 UNITED his box ger to 16. or States Section 17(MENT OF rsuant to Se (a) of the Pt	Wash CHANC ection 16 ublic Uti	nington, GES IN I SECUR (a) of the lity Hold	D.C. 2054 BENEFIC ITIES e Securitie	49 CIAL es Exc pany 2	OWN change Act of	OMMISSION NERSHIP OF e Act of 1934, 1935 or Section 0	OMB Number: Expires: Estimated a burden hou response		
ARMEN GARO H Sy			2. Issuer Name and Ticker or Trading Symbol AGENUS INC [AGEN]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(M			3. Date of Earliest Transaction (Month/Day/Year) 06/29/2016					Director 10% Owner X Officer (give title Other (specify below) below) Chairman & CEO			
				f Amendment, Date Original d(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(State)	(Zip)	Table	I - Non-D	erivative So	curiti	es Acm	uired, Disposed of	or Beneficial	lv Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		ed 2 Date, if 7 y/Year) (3.	4. Securitie n(A) or Disp (Instr. 3, 4)	s Acqu osed c	uired	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Common Stock	06/29/2016			J <u>(1)</u>	152,405	A	\$ 3.63	1,548,883	D		
Common Stock								4,046	Ι	by Holdings	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: AGENUS INC - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	ate	7. Titl Amou Under Secur (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address				
	Director	10% Owner	Officer	Other
ARMEN GARO H 3 FORBES ROAD LEXINGTON, MA 02421			Chairman & CEO)
Signatures				
Christine M. Klaskin, by Powe Attorney	r of	07/	/01/2016	
**Signature of Reporting Person			Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents required distribution from the Garo Armen 2014 2 Year GRAT.

Dr. Armen is Chairman of the Board of Managers and a member of Antigenics Holdings LLC ("Holdings") which as of the date of this
 (2) report owns 4,046 shares of Agenus Inc. common stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Holdings and disclaims beneficial ownership to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.